My watch list  

Canbex Therapeutics Secures TSB Biocatalyst Grant


Canbex Therapeutics Ltd announced that it has secured a grant of £1.25M to further support the development of VSN16R.  Alongside our recent financing round the grant secures the early development of this novel treatment for spasticity in multiple sclerosis.

“The goal of the Canbex programme is to set a new standard in the treatment of spasticity through improved tolerability,” said  Jesse Schulman, CEO of Canbex. “Spasticity is among the most serious and debilitating symptoms of MS. VSN16R, our lead investigational candidate, has the potential to make a difference to people with MS.”

Facts, background information, dossiers
  • Canbex Therapeutics
  • grants
  • multiple sclerosis
  • spasticity
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE